Lixte Biotechnology Holdings Inc LIXT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LIXT is a good fit for your portfolio.
News
-
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
-
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
-
Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research
-
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
-
First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
-
Lixte Bio Shares Jump on LB-100 Trial
Trading Information
- Previous Close Price
- $2.26
- Day Range
- $3.05–4.40
- 52-Week Range
- $1.58–9.60
- Bid/Ask
- $3.30 / $3.35
- Market Cap
- $7.92 Mil
- Volume/Avg
- 6,892 / 626,809
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.lixte.com
Valuation
Metric
|
LIXT
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 16.00 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
LIXT
|
---|---|
Quick Ratio | 13.39 |
Current Ratio | 13.73 |
Interest Coverage | −313.45 |
Quick Ratio
LIXT
Profitability
Metric
|
LIXT
|
---|---|
Return on Assets (Normalized) | −95.73% |
Return on Equity (Normalized) | −642.64% |
Return on Invested Capital (Normalized) | −103.45% |
Return on Assets
LIXT
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wpmqlzyjf | Jzmx | $571.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hklyjvgv | Mkpdgl | $107.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pxhtykxf | Bvwps | $106.1 Bil | |
MRNA
| Moderna Inc | Cjmrgydzx | Zxqzf | $42.3 Bil | |
ARGX
| argenx SE ADR | Yjczwsbj | Kfkl | $23.7 Bil | |
BNTX
| BioNTech SE ADR | Qrrddrkmt | Jfjsl | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dypxjlvb | Wjmcd | $19.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Myqxqtmf | Wjkyqlw | $16.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xjgbktwstc | Nxzsffm | $13.6 Bil | |
INCY
| Incyte Corp | Gjgpjcfm | Cybwbs | $12.8 Bil |